MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 208163 | Name: 5-FU Prodrug 4

Description:

WARNING: This product is for research use only, not for human or veterinary use.

5-FU Prodrug 4 is a palladium-activated 5-FU prodrug. Over the past four decades, several modulation strategies including the implementation of 5-FU-based combination regimens and 5-FU pro-drugs have been developed and tested to increase the anti-tumor activity of 5-FU and to overcome the clinical resistance.

Chemical Structure

5-FU Prodrug 4
5-FU Prodrug 4
CAS#unknown

Theoretical Analysis

MedKoo Cat#: 208163

Name: 5-FU Prodrug 4

CAS#: unknown

Chemical Formula: C10H7FN2O2

Exact Mass: 206.0492

Molecular Weight: 206.18

Elemental Analysis: Chemical Formula: C10H7FN2O2 Exact Mass: 206.0492 Molecular Weight: 206.1764 Elemental Analysis: C, 58.26; H, 3.42; F, 9.21; N, 13.59; O, 15.52

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
5FU Prodrug 4, 5FUProdrug 4
IUPAC/Chemical Name
5-Fluoro-2,4-bis(prop-2-yn-1-yloxy)pyrimidine
InChi Key
UEJQGOKMPMUMTO-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H7FN2O2/c1-3-5-14-9-8(11)7-12-10(13-9)15-6-4-2/h1-2,7H,5-6H2
SMILES Code
C#CCOC1=NC=C(F)C(OCC#C)=N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 206.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther. 2020 Feb;206:107447. doi: 10.1016/j.pharmthera.2019.107447. Epub 2019 Nov 19. PMID: 31756363. 2: Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005 Jan;27(1):23-44. doi: 10.1016/j.clinthera.2005.01.005. PMID: 15763604. 3: Pham T, Plata PL, Zhang P, Vellara A, Bu W, Lin B, Cheng G, Liu Y. Knowledge- Based Design of 5-Fluororacil Prodrug Liposomal Formulation: Molecular Packing and Interaction Revealed by Interfacial Isotherms and X-ray Scattering Techniques. Mol Pharm. 2021 Dec 6;18(12):4331-4340. doi: 10.1021/acs.molpharmaceut.1c00494. Epub 2021 Nov 5. PMID: 34739257. 4: Sun Y, Zhao D, Wang G, Jiang Q, Guo M, Kan Q, He Z, Sun J. A novel oral prodrug-targeting transporter MCT 1: 5-fluorouracil-dicarboxylate monoester conjugates. Asian J Pharm Sci. 2019 Nov;14(6):631-639. doi: 10.1016/j.ajps.2019.04.001. Epub 2019 Apr 25. PMID: 32104489; PMCID: PMC7032090. 5: Budman DR. Capecitabine. Invest New Drugs. 2000 Nov;18(4):355-63. doi: 10.1023/a:1006449315650. PMID: 11081571. 6: Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012 Jun;13(6):579-88. doi: 10.1016/S1470-2045(12)70116-X. Epub 2012 Apr 13. PMID: 22503032. 7: Dean L, Kane M. Capecitabine Therapy and DPYD Genotype. 2016 Sep 15 [updated 2020 Nov 2]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 28520372. 8: Beall HD, Sloan KB. Topical delivery of 5-fluorouracil (5-Fu) by 3-alkylcarbonyl-5-Fu prodrugs. Int J Pharm. 2001 Apr 17;217(1-2):127-37. doi: 10.1016/s0378-5173(01)00609-3. PMID: 11292549. 9: Shirasaka T, Taguchi T. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept]. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:4-18. Japanese. PMID: 16897967. 10: Sasaki E, Tominaga K, Kuwamura H, Watanabe T, Fujiwara Y, Oshitani N, Higuchi K, Arakawa T. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism. J Gastroenterol. 2007 Oct;42(10):816-22. doi: 10.1007/s00535-007-2101-5. Epub 2007 Oct 15. PMID: 17940834.